Hartford Multifactor Diversified International ETF (BATS: RODE)

Latest News for Hartford Multifactor Diversified International ETF (BATS:RODE)

Hartford Multifactor Diversified International ETF

RODEDAWG INTL INDUS INC by Rodedawg International Industries, Inc.

Rodedawg International Industries Inc

News

Financing

Contracts

PHIO

Phio Pharmaceuticals Enters Into Purchase Agreement With TRITON Funds; TRITON To Purchase 18.8% Of Phio's Common Shares Yielding Gross Proceeds Of Up To $621,000

DOMO

Domo Announces IT Solutions Provider Zirous Joins Partner Program; Zirous To Empower Customers With Domo Platform As Certified Reseller, Referral, And Implementation Partner

<ul>
<li>Elon Musk has terminated most of Tesla&#39;s Supercharger team following a conflict with a senior executive.</li>
<li>Despite the recent layoffs, Tesla plans to continue expanding the Supercharger network, with an investment of over $500 million.</li>
<li>Tesla&#39;s stock has been volatile, currently struggling to overcome the $200 mark, which is crucial for potential recovery.</li>
</ul>
In a significant corporate shake-up, Elon Musk has fired most of Tesla Inc&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) Supercharger team after a clash with a senior executive during a business presentation. This incident has sparked concerns about potential disruptions within Tesla&#39;s operations.
The Supercharger network, crucial for supporting Tesla&#39;s electric vehicles, consists of over 6,200 charging facilities worldwide and is a cornerstone of Tesla&#39;s infrastructure.
Despite these layoffs, Tesla remains committed to expanding this vital network. The company has allocated over $500 million solely for the expansion of the Supercharger facilities, not including operational costs. This highlights the scale and importance of Tesla&rsquo;s future plans for the network.
However, the layoffs have caused frustration among contractors and municipal governments that have invested in long-term engagements with the Supercharger network.
Their investments, aligned with Tesla&rsquo;s previous strategic plans, now face uncertainty, potentially affecting future collaborations. In an effort to stabilize the operation, Tesla has started quietly rehiring some members of the Supercharger team.
On the financial side, Tesla&rsquo;s stock performance mirrors the company&#39;s turbulence. The stock has dropped by 29% so far in 2024. In March, it fell to lows of 43% for the year, hitting levels not seen since January 2023.
Currently, the stock is highly volatile, fluctuating between a support level of around $100 and resistance at about $300, which were the lows and highs of 2023. The immediate challenge for Tesla&rsquo;s stock is to surpass the $200 mark, just under $30 above its current level.
Crossing this obstacle is crucial for any potential recovery. Failure to do so might push the stock back towards the $100 support level, and breaking below this level could lead to further declines in market value.
<img alt="2024-05-17_12-33-09.jpg" src="https://www.benzinga.com/files/u517520/2024-05-17_12-33-09.jpg" style="height:345px; width:624px" />
Tesla&#39;s stock would need to rise by 135% to reach its all-time high of $414 in November 2021. Achieving this will require significant effort and strategic management of the company&#39;s current challenges.
After the closing bell on Thursday, May 16, the stock closed at $174.84, trading up by 0.49%.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

TSLA

Elon Musk Cuts Deep Into Tesla's Supercharger Team As Stock Tumbles 29% For The Year

China&#8217;s latest EV entrants are looking to take on Tesla Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) market share within the country, with vehicles priced competitively against the American EV giant&#8217;s best-selling EVs in the country.
What Happened: China is the second largest market for Tesla after the U.S. The more popular Tesla vehicles in the East Asian country are its lower-priced Model 3 sedan and the Model Y SUV. While the competition between Tesla and Chinese EV giant BYD Co has been ongoing, newer players have now joined the race.
Onvo L60 Vs. Model Y: Chinese EV maker Nio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) on Wednesday launched its <a href="https://www.benzinga.com/markets/asia/24/05/38842756/nios-mass-market-ev-brand-will-be-led-by-former-disney-exec-whose-name-literally-means-will-surely-s">new sub-brand Onvo</a>. The brand&#8217;s first car, the L60 mid-size family SUV was also unveiled with a starting price of 219,900 yuan ($30,427), about 12% lower than the Tesla Model Y which starts at 249,900 yuan ($34,578) in the country. The company intends to start delivering the SUV in September. 
&#8220;RAV4 and Model Y were the benchmark for family cars in their time. With technologies evolving and people's understanding in smart EVs deepening, today it's time for us to redefine the new standards for family cars,&#8221; Nio CEO William Li said at the launch event. 
Xiaomi SU7 Vs. Model 3: Chinese tech giant Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) started delivering its SU7 electric send in April. The vehicle has a starting price of <a href="https://www.benzinga.com/news/24/03/38000440/xiaomis-su7-sedan-aims-to-challenge-teslas-model-s-with-price-lower-than-entry-level-model-3" target="_blank" rel="noreferrer noopener">215,900 yuan</a>&nbsp;(about $29,873), nearly 7% lower than the Tesla Model 3 in China. The pricier variants of the sedan, called Pro and Max, start at 245,900 ($34,024) and 299,900 yuan ($41,496), respectively. The priciest version of the Model 3, termed the Performance variant, in contrast, starts at 335,900 yuan (46,477). 
Earlier this week, it was reported that Xiaomi has already delivered its 10,000th EV within 2 months of launch. Xiaomi CEO Lei Jun predicted&nbsp;<a href="https://www.benzinga.com/markets/asia/24/04/38064533/xiaomi-ceo-predicts-tesla-like-success-as-chinese-ev-debutants-1st-electric-offering-zooms-off-the-l" target="_blank" rel="noreferrer noopener">Tesla-like success</a>&nbsp;for the SU7 last month. The company intends to deliver 100,000 units of the sedan this year.
Why It Matters: In the first four months of this year, BYD sold 434,579 battery-electric vehicles and NIO delivered 45,673 vehicles. As per data from the China Passenger Car Association, Tesla sold 163,841 units in China in the meantime. 
China is Tesla&#8217;s second-largest market after the U.S. The company relies heavily on sales as well as production within China to maintain its position as the global best-selling battery electric vehicle seller. The company, however, has been <a href="https://www.benzinga.com/markets/equities/24/04/38348232/tesla-aggressively-cuts-prices-ahead-of-q1-report-ev-maker-lowers-model-3-y-prices-in-china-by-u">relying on price cuts to drive sales </a>across its key markets in light of increased competition. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/05/38891146/teslas-german-factory-expansion-gets-local-councils-nod-despite-protests">Tesla&#8217;s German Factory Expansion Gets Local Council&#8217;s Nod Despite Protests</a>
Image Created Using Midjourney

Tech

XIACF

Tesla Faces Stiff Price Competition In China From Latest Entrants Nio's Onvo L60 And Xiaomi SU7

<ul>
<li>A Change-in-control and Spin-Off of Slinger Bag also receives Shareholder Consent</li>
<li>The close of these transactions remains subject to Nasdaq Approval</li>
</ul>

Connexa Sports Technologies Inc. - Common Stock

YYAI

Connexa Sports Technologies To Acquire Yuanyu Enterprise Management; To Issue 162.6M Shares To YYEM To Complete Transaction

Piper Sandler analyst Charles Neivert maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Underweight and raises the price target from $54 to $56.

Price Target

Analyst Ratings

Piper Sandler Maintains Underweight on Nutrien, Raises Price Target to $56

Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Silence Therapeutics, presenting an average target of $57.0, a high estimate of $75.00, and a low estimate of $42.00. Observing a 31.34% increase, the current average has risen from the previous average price target of $43.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950857_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Silence Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Silence Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Silence Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Silence Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Silence Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Silence Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Silence Therapeutics: A Closer Look</h2>
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
<h3>Silence Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Silence Therapeutics's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -55.95% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Silence Therapeutics's net margin excels beyond industry benchmarks, reaching -686.61%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -77.8%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Silence Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -15.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Silence Therapeutics's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Silence Therapeutics

During the last three months, 13 analysts shared their evaluations of Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $130.15, a high estimate of $144.00, and a low estimate of $121.00. Observing a 6.46% increase, the current average has risen from the previous average price target of $122.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950849_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amphenol. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$144.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$124.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$121.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amphenol. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amphenol compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Amphenol's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Amphenol's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amphenol analyst ratings.</a>
<h2>Get to Know Amphenol Better</h2>
Amphenol is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.
<h3>Unraveling the Financial Story of Amphenol</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Amphenol's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 9.49%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.85%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Amphenol's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amphenol's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Amphenol adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Amphenol's Future

5 analysts have expressed a variety of opinions on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $190.4, a high estimate of $200.00, and a low estimate of $180.00. Highlighting a 0.18% decrease, the current average has fallen from the previous average price target of $190.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950840_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of AbbVie by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$187.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$188.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into AbbVie's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AbbVie analyst ratings.</a>
<h2>Get to Know AbbVie Better</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.7% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.04%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching 14.8%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.96%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AbbVie's debt-to-equity ratio is notably higher than the industry average. With a ratio of 9.24, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

The Analyst Verdict: AbbVie In The Eyes Of 5 Experts

In the last three months, 27 analysts have published ratings on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $446.7, a high estimate of $550.00, and a low estimate of $272.00. This current average has decreased by 4.58% from the previous average price target of $468.16. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950834_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of MongoDB by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$470.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$465.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$465.00</td>
<td>-</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$415.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Turits</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$440.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$465.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$495.00</td>
</tr>
<tr>
<td>Alex Haissl</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Sell</td>
<td>$295.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$435.00</td>
<td>-</td>
</tr>
<tr>
<td>Firoz Valliji</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$491.00</td>
<td>$484.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$440.00</td>
<td>-</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$475.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$490.00</td>
<td>$543.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$475.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$385.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$465.00</td>
<td>$495.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$458.00</td>
<td>$478.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$272.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$440.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MongoDB. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of MongoDB compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MongoDB's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of MongoDB's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MDB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MongoDB analyst ratings.</a>
<h2>Delving into MongoDB's Background</h2>
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
<h3>MongoDB's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: MongoDB displayed positive results in 3 months. As of 31 January, 2024, the company achieved a solid revenue growth rate of approximately 26.76%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: MongoDB's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.11% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): MongoDB's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.45%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): MongoDB's ROA stands out, surpassing industry averages. With an impressive ROA of -1.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: MongoDB's debt-to-equity ratio is below the industry average. With a ratio of 1.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 27 Analyst Recommendations For MongoDB

Domino's Pizza's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) short percent of float has risen 10.33% since its last report. The company recently reported that it has 1.45 million shares sold short, which is 4.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Domino's Pizza Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715950823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Domino's Pizza has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Domino's Pizza's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Domino's Pizza's peer group average for short interest as a percentage of float is 10.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Domino's Pizza?

Across the recent three months, 15 analysts have shared their insights on Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Klaviyo, revealing an average target of $34.73, a high estimate of $40.00, and a low estimate of $25.00. Highlighting a 6.96% decrease, the current average has fallen from the previous average price target of $37.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950820_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Klaviyo by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Shebly Seyrafi</td>
<td>FBN Securities</td>
<td>Announces</td>
<td>Outperform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Klaviyo. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Klaviyo compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Klaviyo's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Klaviyo's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KVYO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Klaviyo analyst ratings.</a>
<h2>Get to Know Klaviyo Better</h2>
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
<h3>Breaking Down Klaviyo's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Klaviyo's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 34.53%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Klaviyo's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6.13%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Klaviyo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.39%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.17%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KVYO

The Analyst Landscape: 15 Takes On Klaviyo

MicroCloud Hologram's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NYSE">HOLO</a>) short percent of float has risen 74.9% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 34.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MicroCloud Hologram Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715950818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MicroCloud Hologram has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing MicroCloud Hologram's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MicroCloud Hologram's peer group average for short interest as a percentage of float is 2.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Peering Into MicroCloud Hologram's Recent Short Interest

Philip Morris Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) short percent of float has risen 25.0% since its last report. The company recently reported that it has 9.24 million shares sold short, which is 0.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Philip Morris Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715950811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Philip Morris Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Philip Morris Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Philip Morris Intl's peer group average for short interest as a percentage of float is 2.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Philip Morris Intl's Recent Short Interest

Mortgage applications for vacation properties plummeted 40% in 2023, according to a Redfin report issued Monday, marking a downturn in a market that once flourished during the pandemic boom. Demand for second-home mortgages fell twice as fast as the demand for primary homes, the report found, as <a href="https://www.benzinga.com/general/24/04/38277365/grant-cardone-gives-7-reasons-why-you-should-rent-instead-of-buying-a-home">housing costs reached all-time highs</a>. Data tracked for this year shows that the trend has not reversed, with interest in second-home mortgages remaining near an eight-year low.
U.S. homebuyers took out just under 91,000 mortgages for second homes throughout 2023, down 40% from the previous year and two-thirds from 2021, as market participants face high mortgage rates, low inventory, and record-high home prices.&nbsp;
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Here's how you can collect passive rental income without being a landlord</a>.</li>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
 "Soaring prices pushed down demand for vacation homes last year, both for cash buyers and those getting a mortgage," Redfin Premier agent Heather Mahmood-Corley said on Monday. The typical second home was valued at just under $500,000 in 2023, Redfin noted, much higher than the $375,000 average for primary homes. That cost disparity is a major factor deterring potential buyers from entering the market, particularly those dependent on financing. 
As a result, just 3% of all mortgages in 2023 went to second-home buyers, a drop from 5% in 2020. Primary homebuyers accounted for nearly nine out of 10 mortgages in 2023, with the remainder going to investment properties.
 Demographically, <a href="https://www.benzinga.com/real-estate/reit/24/04/38047304/unlocking-wealth-millennials-new-path-to-prosperity-with-real-estate">high-income buyers dominated the market</a>, with nearly 86% of second-home mortgages going to the group. Gen Xers — those aged 43 to 58 in 2023 — were the largest age group of buyers, kick-starting nearly 58% of vacation-home mortgages. The rising cost of living and economic uncertainties have further exacerbated the decline, with many prospective buyers choosing to delay their purchases.
<h2 class="wp-block-heading">Trending:</h2>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
Regionally, Austin, Texas, saw the highest decline in second-home mortgages, with a 62.5% year-over-year drop in 2023. The city&#8217;s housing market, which had boomed during the pandemic due to an influx of remote workers, has slowed as migration trends reversed and housing costs climbed. Other major cities seeing substantial declines include San Francisco, New York, Seattle, and Nashville, according to the report.
In contrast, relatively affordable metros in the middle of the country and on the East Coast saw smaller declines in second-home mortgages. St. Louis, Kansas City, Providence, Montgomery County, and Warren each reported drops between 25% and 32%.
Florida remained a popular destination for second-home buyers, with West Palm Beach leading the pack. Just under 7% of all mortgage originations in West Palm Beach in 2023 were for second homes, followed by Orlando, Riverside, New Brunswick, and Tampa. As mortgage rates continue to hover near 7%, the outlook for the vacation home market remains uncertain. "People who would need a mortgage are still sitting on the sidelines, waiting for rates to come down — especially because rates are typically even higher for second homes than primary homes," Mahmood-Corley said. 
Read Next:
<ul>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to this <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Jeff Bezos-backed startup to generate monthly rental income without having to purchase their own property</a>.</li>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000. </a></li>
</ul>

Real Estate

Vacation-Home Buyers Retreat Amid Soaring Interest Rates

During the last three months, 5 analysts shared their evaluations of Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $442.4, along with a high estimate of $494.00 and a low estimate of $387.00. This current average reflects an increase of 8.7% from the previous average price target of $407.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715950808_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Deere by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$456.00</td>
<td>-</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$425.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$494.00</td>
<td>-</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$387.00</td>
<td>$381.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Deere. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Deere compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Deere's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Deere's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Deere analyst ratings.</a>
<h2>Unveiling the Story Behind Deere</h2>
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
<h3>Key Indicators: Deere's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Deere's revenue growth over a period of 3 months has faced challenges. As of 31 January, 2024, the company experienced a revenue decline of approximately -4.44%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Deere's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Deere's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.98%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Deere's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.7%, the company showcases efficient use of assets and strong financial health.
Debt Management: Deere's debt-to-equity ratio surpasses industry norms, standing at 2.87. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Deere

WHLRL

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Piper Sandler analyst Nathan Rice reiterates Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) with a Overweight and lowers the price target from $58.5 to $56.

Reiteration

MBIN

Piper Sandler Reiterates Overweight on Merchants Bancorp, Lowers Price Target to $56

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommends buying sports betting company DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), proclaiming, &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38770327/sports-betting-sector-could-see-duopoly-or-oligopoly-in-most-states-goldman-sachs-a">I think it's terrific</a>.&#8221;
On May 2, DraftKings reported first-quarter revenue of $1.18 billion, up 53% year-over-year. The revenue total beat a Street consensus estimate of $1.12 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
The global online sports betting market size had a value of roughly $54.6 billion in 2023. It&#8217;s projected to exceed $142 billion by 2032, per Zion Market Research. 
Cramer also called Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) &#8220;<a href="https://www.benzinga.com/markets/equities/24/05/38783794/amazon-pours-1-3b-investment-into-french-operations-report">too low.&#8221;</a>
On May 15, Deutsche Bank analyst Bryan Keane downgraded Accenture from Buy to Hold and lowered the price target from $409 to $295.
When asked about Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>), Cramer said, &#8220;I can't go there, because I'm not recommending stocks where they just have not been able to even get near a profit.&#8221;
On May 9, Ouster reported better-than-expected financial results for the first quarter.
The &#8220;Mad Money&#8221; host he needs to do work on Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) as &#8220;this thing has been such a rocket ship. I cant' just say it's moved to much. I've got to learn it better.&#8221;
On May 8, Vistra posted results for the first quarter, recording quarterly sales of $3.054 billion versus market expectations of $2.778 billion.
MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) has been &#8220;disappointing,&#8221; Cramer said. &#8220;I don't like to be betting behind losing horses.&#8221;
On May 2, MP Materials posted mixed results for its first quarter, reporting adjusted loss of 4 cents per share, wider than market expectations for a loss of 2 cents per share.
Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is just &#8220;doing so well, they have an amazing cardio franchise,&#8221; Cramer said, &#8220;It is just fantastic.&#8221;
On April 24, Boston Scientific reported better-than-expected first-quarter earnings and issued guidance.
Price Action:
<ul>
<li>Accenture shares fell 0.2% to settle at $308.00 on Thursday.</li>
<li>Ouster shares fell 3.6% to close at $11.66.</li>
<li>Vistra shares declined 3.9% to settle at $93.14 on Thursday.</li>
<li>DraftKings shares fell 2.6% to settle at $44.97.</li>
<li>MP Materials shares rose 0.8% to close at $18.08 on Thursday.</li>
<li>Boston Scientific shares gained 0.1% to settle at $74.55.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/05/38872018/top-5-utilities-stocks-you-may-want-to-dump-in-may">Top 5 Utilities Stocks You May Want To Dump In May</a>
Image: Shutterstock

Long Ideas

Markets

Media

DKNG

OUST

Jim Cramer Recommends Buying This Sports Betting Company's Stock: 'I Think It's Terrific'

Scotiabank analyst Greg McGinniss downgrades Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) from Sector Perform to Sector Underperform and lowers the price target from $16 to $14.